Top US health officials believe that Pfizer’s COVID-19 vaccine may be approved for children ages 5 to 11 by the end of October, sources familiar with the matter said.
The projection is based on the expectation that the drug-maker will have enough data to seek an Emergency Use Authorization [EUA] from the Food and Drug Administration by the end of the month, sources told Reuters.
Regulators would then likely make a decision within three weeks of the submission.
The decision about whether to vaccinate younger children comes amid pressure to contain a surge of infections caused by the Delta variant, which has complicated efforts for schools to return to classes.
Dr. Anthony Fauci, the White House chief medical advisor, previously outlined a similar timeline for the decision during an online town hall meeting with thousands of colleagues at the National Institutes of Health, a source said.